These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 23157756)

  • 21. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
    Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
    J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Rare Case of Pleomorphic Carcinoma of the Lung Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement.
    Shiroyama T; Tanaka A; Tamiya M; Hamaguchi M; Osa A; Takeoka S; Tani E; Azuma Y; Morishita N; Suzuki H; Okamoto N; Kimura K; Kadota Y; Kawahara K; Hirashima T; Kawase I
    Intern Med; 2015; 54(21):2741-3. PubMed ID: 26521903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangements.
    Riess JW; Padda SK; Bangs CD; Das M; Neal JW; Adrouny AR; Cherry A; Wakelee HA
    Clin Lung Cancer; 2013 Sep; 14(5):592-5. PubMed ID: 23810364
    [No Abstract]   [Full Text] [Related]  

  • 24. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
    Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A
    Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.
    Xu C; Buczkowski KA; Zhang Y; Asahina H; Beauchamp EM; Terai H; Li YY; Meyerson M; Wong KK; Hammerman PS
    Mol Cancer Ther; 2015 Oct; 14(10):2382-2389. PubMed ID: 26206333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
    Kuiper JL; Ronden MI; Becker A; Heideman DA; van Hengel P; Ylstra B; Thunnissen E; Smit EF
    J Clin Pathol; 2015 Apr; 68(4):320-1. PubMed ID: 25661795
    [No Abstract]   [Full Text] [Related]  

  • 28. EGFR mutation testing for squamous cell lung carcinoma.
    Liam CK; Leow HR; Pang YK
    J Thorac Oncol; 2013 Dec; 8(12):e114. PubMed ID: 24389448
    [No Abstract]   [Full Text] [Related]  

  • 29. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
    J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract]   [Full Text] [Related]  

  • 30. Does the addition of vascular endothelial growth factor inhibitors to epidermal growth factor receptor-tyrosine kinase inhibitor overcome T790M acquired resistance?
    Hata A; Kaji R; Fujita S; Katakami N
    J Thorac Oncol; 2011 Feb; 6(2):404. PubMed ID: 21252723
    [No Abstract]   [Full Text] [Related]  

  • 31. Combining inhibitors of ALK and ROS1 with other agents for the treatment of non-small cell lung cancer.
    Shaw AT
    Clin Adv Hematol Oncol; 2015 May; 13(5):282-4. PubMed ID: 26352769
    [No Abstract]   [Full Text] [Related]  

  • 32. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological management of relapsed/refractory NSCLC with chemical drugs.
    Karachaliou N; Sosa AE; Barron FB; Gonzalez Cao M; Santarpia M; Rosell R
    Expert Opin Pharmacother; 2017 Feb; 18(3):295-304. PubMed ID: 28103738
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
    Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
    J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].
    Ostoros G; Döme B; Strausz J; Tímár J
    Magy Onkol; 2010 Jun; 54(2):137-43. PubMed ID: 20576590
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer. A bull's eye for targeted lung cancer therapy.
    Minna JD; Gazdar AF; Sprang SR; Herz J
    Science; 2004 Jun; 304(5676):1458-61. PubMed ID: 15178790
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
    Toyooka S; Uchida A; Shigematsu H; Soh J; Ogino A; Takata M; Kiura K; Ouchida M; Kosaka T; Aoe M; Mitsudomi T; Date H
    J Thorac Oncol; 2007 Apr; 2(4):321-4. PubMed ID: 17409805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 39. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
    Chuang JC; Neal JW; Niu XM; Wakelee HA
    Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.